Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human acellular vessel - Humacyte

X
Drug Profile

Human acellular vessel - Humacyte

Alternative Names: Acellular Tissue Engineered Vessel - Humacyte; ATEV; HAV; HAVG graft implantation; HUMACYL™; HUMAGRAFT™; Human acellular vascular graft - Humacyte; HUMAPASS™

Latest Information Update: 08 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Humacyte
  • Class Tissue transplantation therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Vascular injuries
  • Phase III Renal failure
  • Phase II Peripheral arterial disorders
  • Preclinical Cardiovascular disorders; Congenital heart defects; Type 1 diabetes mellitus

Most Recent Events

  • 01 Jul 2024 Human acellular vessel - Humacyte receives Regenerative Medicine Advanced Therapy (RMAT) status for Peripheral arterial disorders in USA
  • 13 Feb 2024 FDA assigns PDUFA action date of 10/08/2024 for Human acellular vessel for Vascular Trauma (Implant)
  • 12 Feb 2024 Preregistration for Vascular injuries in USA (Implant)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top